Evidence map›Paper›PMID 30885978›Full record

ArticleCancer research2019

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1

Shili Xu, Tianyuan Zhou, Hanna M Doh, K Ryan Trinh, Art Catapang, Jason T Lee, Daniel Braas, Nicholas A Bayley, Reiko E Yamada, Alex Vasuthasawat and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Shili XuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Tianyuan ZhouDepartment of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California.
Hanna M DohDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
K Ryan TrinhMicrobiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles.
Art CatapangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Jason T LeeDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Daniel BraasDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Nicholas A BayleyDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Reiko E YamadaDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles.ORCID 0000-0002-2680-6972
Alex VasuthasawatMicrobiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles.
Joshua P SasineJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.ORCID 0000-0001-9866-462X
John M TimmermanJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.
Sarah M LarsonJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.
Youngsoo KimDepartment of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California.
A Robert MacLeodDepartment of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California.
Sherie L MorrisonMicrobiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles.
Harvey R HerschmanDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles. hherschman@mednet.ucla.edu.
University of California, Los Angeles · USIonis Pharmaceuticals (United States) · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myelomaR01CA200910 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORRISON, SHERIE L · 2016 to 2020
$1.8M
NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA200910
6 · The paper itself

Abstract

Although the majority of adult tissues express only hexokinase 1 (HK1) for glycolysis, most cancers express hexokinase 2 (HK2) and many coexpress HK1 and HK2. In contrast to HK1

Indexed as

Synthetic Lethal MutationsAnimalsCell Line, TumorCell ProliferationHexokinaseHumansMiceMultiple MyelomaOligonucleotides, AntisenseXenograft Model Antitumor AssaysHexokinaseHK2 protein, humanOligonucleotides, Antisense

Identifiers

PMID30885978
PMCPMC6522331
OpenAlexW2922280173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.